Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

Background. Ataxia telangiectasia mutated (ATM) kinase orchestrates DNA double strand break (DSB) repair; ATM inhibitors may therefore enhance the therapeutic effect of DSB-inducing treatments such as radiotherapy (RT). M3541 is an orally administered selective inhibitor of ATM. Methods. This phase ...

Descripción completa

Detalles Bibliográficos
Autores principales: Waqar, Saiama N., Robinson, Clifford, Olszanski, Anthony J., Spira, Alexander, Hackmaster, Melissa, Lucas, Luisa, Sponton, Laura, Jin, Hulin, Hering, Ursula, Cronier, Damien, Grinberg, Marianna, Seithel-Keuth, Annick, Diaz-Padilla, Ivan, Berlin, Jordan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098584/
https://www.ncbi.nlm.nih.gov/pubmed/35150356
http://dx.doi.org/10.1007/s10637-022-01216-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098584/
https://www.ncbi.nlm.nih.gov/pubmed/35150356
http://dx.doi.org/10.1007/s10637-022-01216-8

Ejemplares similares